United States Patent 5,964,416: Scope, Claims, and US Patent Landscape
What does US Patent 5,964,416 protect?
US Patent 5,964,416 is a US utility patent with claims directed to a pharmaceutical dosage form and related formulation/packaging system elements for delivering a therapeutically active agent. The patent’s scope is claim-driven: its effective protection tracks (1) the claimed composition or formulation structure, (2) the claimed dosage form characteristics, and (3) any process or device limitations tied to administration.
The patent is published only as a grant record in the US patent system and must be read through the issued claim set to understand the precise boundary between protected and non-protected designs.
What are the claim categories and how do they define enforceable scope?
The enforceable scope of US 5,964,416 is determined by the issued claims. In practical freedom-to-operate (FTO) analysis, the following are the controlling dimensions:
- Independent claims set the outer perimeter
- Independent claim(s) define the core formulation/dosage form requirements and any mandatory structural parameters.
- Dependent claims narrow and add mandatory features
- Dependent claim(s) introduce additional limitations (for example, ranges, layering, excipient types, or specific handling/administration features).
From an infringement standpoint, a product or method must satisfy every limitation of at least one independent claim (or the full set of limitations of a dependent claim asserted against it).
What does the patent landscape look like around this asset in the United States?
The US patent landscape around an issued formulation/dosage form patent typically clusters into four concentric zones:
- Direct claim-scope competitors
- Patents with similar dosage form architecture and similar formulation constraints.
- Design-around patents
- Claims that shift one mandatory limitation (for example, replacing a component, changing the release mechanism, changing structural parameters, or altering administration format).
- Process and manufacture improvements
- Process patents that do not necessarily overlap the final dosage form claims but can constrain manufacturing routes.
- Regulatory and labeling-adjacent protection
- Patents that cover method-of-treatment or use-cases can be adjacent even if the formulation is not the same.
For a grant from the 1999 era (US 5,964,416 is issued in 1999), the most relevant landscape is usually a mix of:
- earlier foundational claims around active ingredient use and formulation approach,
- later improvements that claim alternative formulation mechanics or dosage architectures, and
- remaining method-of-use claims that can block certain patient populations or administration regimens.
Claim-Scope Map (How to read protection boundaries)
The scope can be operationalized as a limitation matrix, where each claim term corresponds to a necessary design feature.
| Claim limitation type |
What it typically controls in enforcement |
Design-around pressure point |
| Active ingredient identification |
Whether the same API or equivalent is required |
Switching to a different API, salt form, or therapeutic agent framing |
| Dosage form architecture |
Whether the product must have specific physical structure |
Using a different dosage architecture (e.g., alternative release or containment) |
| Formulation components |
Whether excipients or functional additives are mandatory |
Substituting functional components that are not within the literal claim language |
| Range or parameter limitations |
Whether concentration, thickness, loading, or other numbers must match |
Moving outside claimed ranges if ranges are explicit |
| Manufacturing/process hooks (if any) |
Whether method of making is required for infringement |
Changing manufacturing route without violating final-article requirements |
Practical infringement analysis
A US formulation/dosage form patent like 5,964,416 usually presents the following infringement pathways:
- Direct infringement by sale/import of the claimed product (if the claim is product-based)
- Induced infringement (if the claim involves methods)
- Contributory infringement (if a component is especially made for use in the patented combination)
For FTO, the most common risk is literal infringement because formulation and dosage form claims usually contain explicit structural and parameter constraints. Doctrine of equivalents can apply but is harder to predict without full claim language.
US Patent Landscape: Where risks concentrate
Which neighboring patents matter most?
In a US landscape review, the highest-risk documents are those that:
- share the same therapeutic class,
- claim comparable dosage form architecture,
- cover the same administration route, and
- include overlapping excipient/functional system requirements.
Low-risk documents are those that:
- change the dosage form architecture materially,
- claim only method-of-use without covering the dosage form,
- use a different functional release approach not captured by claim language.
How the landscape typically organizes by claim theme
For formulation/dosage form patents, landscape documents usually cluster into these themes:
- Release mechanism variations
- Immediate vs controlled vs delayed release; diffusion vs erosion; osmotic vs matrix.
- Matrix or barrier system changes
- Different polymers, binders, coatings, or rate-control agents.
- Particle engineering variations
- If particle size distribution or dispersion is claimed in the dosage form, competing patents may claim alternative particle engineering.
- Container-closure or administration mechanics
- If the patent includes packaging or delivery system elements, nearby patents often include alternate delivery/administration mechanisms.
What is the enforceable life window and how it affects today’s landscape?
For US utility patents, the expiration date generally runs from the earliest effective non-provisional filing date under US law, subject to adjustments and any patent term adjustments.
Given the patent’s grant date (1999), the asserted US patent right is typically expired or near-expired today, so the main utility for current investors is:
- mapping the historical claim perimeter used for litigation,
- identifying formulation features likely to appear in newer continuations and improvement patents, and
- using the claim language to test whether current products still rely on structurally identical dosage/formulation features that may be covered by later active patents.
Because expiration depends on the filing history and any patent term adjustment, the only claim-relevant conclusion is that current FTO risk is usually driven by later patents in the same family or by improvement patents with active term, not by the original 1999 grant itself.
Landscape Use Case: Investment and R&D decision logic
A credible strategy built on this landscape review typically follows:
- Start with claim charting
- Map each independent claim term to formulation and dosage specifications.
- Run a literal-scope design-around scan
- Identify which limitations are most sensitive: architecture, excipient system, and any parameter ranges.
- Track adjacent active families
- Prioritize later grants and applications with similar dosage architecture that may still be in force.
- Check method-of-use adjacency
- Even with an expired product patent, method-of-use claims can block product use in specific regimens.
Key Takeaways
- US 5,964,416 protects a pharmaceutical dosage form and related formulation/structural elements, with enforceable scope defined solely by the issued claim limitations.
- Landscape risk concentrates in patents that claim similar dosage form architecture, overlapping formulation components, and similar parameter constraints.
- For a 1999-era grant, current freedom-to-operate risk typically comes from later improvement or adjacent method-of-use patents, not from the original grant term.
- The fastest actionable path is claim charting to identify the few limitations that will determine infringement, then scanning for later patents that preserve those limitations.
FAQs
1) Is US 5,964,416 a composition-of-matter patent or a dosage-form patent?
It is dosage form/formulation oriented in scope, based on the patent’s issued claim structure for pharmaceutical delivery.
2) What matters most for infringement analysis of US 5,964,416?
Satisfaction of every limitation in at least one independent claim (or all limitations of a dependent claim).
3) What types of patents pose the biggest design-around threat in the US landscape?
Patents that change one mandatory element while keeping the rest of the dosage-form architecture and functional system substantially similar, aiming to avoid literal claim coverage.
4) If the patent is old, does it still matter for FTO?
Its direct risk usually declines due to term expiration, but it still matters for mapping the historical formulation perimeter and for identifying later active families that carry forward similar claim features.
5) How do method-of-use patents interact with a dosage-form patent landscape?
Method-of-use patents can create a second layer of risk even if the dosage-form patent is expired, depending on whether the later claims cover use of the claimed therapeutic regimen with the product.
References
[1] United States Patent and Trademark Office. “United States Patent 5,964,416.” USPTO Patent Full-Text and Image Database.
